The SPEARHEAD-1 trial reported an overall response rate of 43%, with a complete response rate of 4.5%. How do these response rates compare with existing treatments for synovial sarcoma, and what do they suggest about the potential effectiveness of TECELRA in this patient population?

In the trial, the median duration of response was reported as 6 months, with 39% of responders maintaining their response for 12 months or longer. How significant is this duration of response for patients with advanced synovial sarcoma, and what factors might contribute to this extended response time?

Given that TECELRA was approved for patients who have previously undergone chemotherapy, how does this new therapy address the challenges faced by patients with treatment-resistant synovial sarcoma, particularly those who have exhausted other treatment options?

TECELRA has been associated with several serious side effects, including cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS). How do these risks compare to those of other cell therapies, and what protocols are in place to manage these potential adverse effects during treatment?

The approval of TECELRA is contingent on specific HLA types and MAGE-A4 antigen expression. How does the requirement for biomarker testing influence the selection of patients for this therapy, and what are the implications for broadening access to TECELRA?

TECELRA received FDA accelerated approval based on ORR and duration of response. What are the next steps in confirming its clinical benefit, and how might future trials influence its standing in the treatment landscape for synovial sarcoma?

TECELRA is noted as the first approved engineered cell therapy for a solid tumor. How does it compare to other T cell therapies in development, particularly those targeting different types of cancers, and what does this approval signify for the future of cell-based treatments in oncology?

Considering the aggressive nature of synovial sarcoma and its impact on younger patients, how might TECELRA improve not only survival outcomes but also the quality of life for these patients? What feedback have you received from patients regarding their experiences with this new therapy?